http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20130032758-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_665a1ccbeb11cc1bcdd3c4d078d4e3f0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2011-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f907537419a7a5c771b9d33e17ee851f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_495bb160488866fb171b0d302df42f48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71b64606f0102a8ef414c37ee8d77924 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd2a33e84e2ea14a8deb427aa68bfe3f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f577a6cb21a828c6e009306d3ead25fc |
| publicationDate | 2013-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20130032758-A |
| titleOfInvention | Pharmaceutical composition for the prophylaxis or treatment of prion diseases containing a PrP gene as an active ingredient using a recombinant adenovirus vector |
| abstract | The present invention relates to a pharmaceutical composition for preventing or treating prion diseases containing a PrP gene as an active ingredient using a recombinant adenovirus vector. The system in which the PrNP gene was transfected into the Prnp gene knock-out mouse neuronal cell line (Zpl 3-4) using the recombinant adenovirus vector according to the present invention overexpresses PrP C in the normal oxygen state, and annexin V ( +) The percentage of cells, ie cells in which apoptosis has occurred, and the activity of LDH are significantly reduced than in Zpl 3-4 cells transfected with a recombinant adenovirus vector (Ad-lacZ) without an expression cassette. Therefore, the transfection system of the PrNP gene using the recombinant adenovirus vector according to the present invention protects neurons by inhibiting PrP Sc -mediated neuronal cell death, and thus can be usefully used for the prevention or treatment of prion diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190127266-A |
| priorityDate | 2011-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.